-=REGENXBIO (RGNX) reported earnings on Tue 6 March 2018 (a/h)

REGENXBIO reports smaller-than-expected loss, revs rise 23% YoY 

• Reports Q4 (Dec) loss of ($0.51) per share, $0.31 better than the Capital IQ Consensus loss of ($0.82); revenues rose 22.5% year/year to $2.0 mln vs the $0.75 mln Capital IQ Consensus
• Cash, cash equivalents and marketable securities were $176.4 million as of December 31, 2017, compared to $159.0 million as of December 31, 2016

Financial Guidance:

• REGENXBIO reiterates that it expects full-year 2018 cash burn to be between $85 million and $95 million, which will support the continued development of its lead product candidate programs
• Full-year 2018 cash burn guidance excludes the effect of the upfront payment of $80 million and any other potential consideration that may be received from AveXis in connection with the previously announced amendment to the license agreement in January 2018 for the development and commercialization of treatments for SMA
• Subject to this exclusion, full-year 2018 cash burn will be measured as the decrease in cash, cash equivalents and marketable securities from December 31, 2017 to December 31, 2018